Browsing by Author "Igdem, S."

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Metastases directed SBRT using Ga68-PSMA for oligometastatic prostate cancer: TROD 09-002 Study
    (ELSEVIER IRELAND LTD, 2019-01-01) Ozyigit, G.; Igdem, S.; Atalar, B.; Ozkok, H. B.; Hurmuz, P.; Akyol, F.
  • Thumbnail Image
    Item
    The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
    (ELSEVIER IRELAND LTD, 2017-01-01) Ozyigit, G.; Onal, C.; Igdem, S.; Alicikus, Z. Arican; Iribas, A.; Akin, M.; Yalman, D.; Cetin, I.; Aksu, M. G.; Atalar, B.; Dincbas, F.; Aydin, B.; Sert, F.; Yildirim, C.; Gorken, I. B.; Agaoglu, F. Y.; Korcum, A. F.; Ozkok, S.; Darendeliler, E.; Akyol, F.
  • Thumbnail Image
    Item
    Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
    (OXFORD UNIV PRESS, 2011-01-01) Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.
    Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.